A Long-term Outcomes Study to Assess Statin Residual Risk Reduction with EpaNova High Cardiovascular Risk Patients witgh Hypertriglyceridemia (STRENGTH)

Project Details

StatusFinished
Effective start/end date8/06/15 → 30/06/24

Funding

  • Astra Zeneca: $145,073.50

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research